Autobahn Therapeutics

NEWS

Biotech Beach

Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B

This morning, the company officially launched with a Series B funding round backed by some of the biggest names in the life sciences, including Bristol Myers Squibb, Biogen and Pfizer.

June 9, 2020

·

2 min read

·

JOBS

IN THE PRESS

Biotech Beach

Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

September 6, 2023

·

1 min read

Drug Development

Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial

April 18, 2023

·

3 min read

Biotech Beach

Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days

March 23, 2023

·

1 min read

Drug Development

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder

November 29, 2022

·

4 min read

Biotech Beach

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression

September 8, 2022

·

5 min read

Drug Development

Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination

May 18, 2022

·

3 min read

Biotech Beach

Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting

March 3, 2022

·

3 min read

Biotech Beach

Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders

November 3, 2021

·

4 min read

Business

Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders

September 14, 2021

·

4 min read

FDA

Autobahn Therapeutics Announces Orphan Drug Designation Granted to ABX-002 for the Treatment of X-linked Adrenoleukodystrophy

August 2, 2021

·

2 min read